Eton Pharmaceuticals, Inc. (ETON)

Market Cap	719.22M +100.4%
Revenue (ttm)	79.95M +104.9%
Net Income	-4.60M
EPS	-0.17
Shares Out	27.28M
PE Ratio	n/a
Forward PE	35.62
Dividend	n/a
Ex-Dividend Date	n/a

Volume	399,868
Open	27.09
Previous Close	27.10
Day's Range	26.04 - 27.11
52-Week Range	11.38 - 27.19
Beta	0.97
Analysts	Strong Buy
Price Target	39.33 (+49.2%)
Earnings Date	May 12, 2026

About ETON

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing vari...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 13, 2018
• Employees: 44
• Stock Exchange: NASDAQ
• Ticker Symbol: ETON
• Website: https://www.etonpharma.com

Financial Performance

In 2025, Eton Pharmaceuticals's revenue was $79.95 million, an increase of 104.94% compared to the previous year's $39.01 million. Losses were -$4.60 million, 20.4% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for ETON stock is "Strong Buy." The 12-month stock price target is $39.33, which is an increase of 49.20% from the latest price.

Price Target

$39.33

(49.20% upside)

Analyst Consensus: Strong Buy